Clinical Trial for Pneumococcal Disease.

The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC). This vaccine will be given as per the age-specific dosing schedules among healthy adults, children and infants in China.

This study is seeking healthy participants of 5 specific age groups:

Group 1: Adults ≥18 to <50 years of age
Group 2: Children ≥2 to <6 years of age
Group 3: Children ≥12 months to <2 years of age
Group 4: Infants ≥7 to <12 months of age
Group 5: Infants ≥42 to ≤98 days of age

All participants in this study will receive 20vPnC as per the age-specific dosing schedules:

Group 1: participants will receive 1 dose of 20vPnC.
Group 2: participants will receive 1 dose of 20vPnC.
Group 3: participants will receive 2 doses of 20vPnC. Dose 2 will be given 56 to 70 days after Dose 1.
Group 4: participants will receive 3 doses of 20vPnC. Dose 2 will be given 28 to 56 days after Dose 1, and Dose 3 will be given at 365 to <455 days of age and at least 56 days after Dose 2.
Group 5: participants will receive 4 doses of 20vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to <455 days of age.

The study will look at the experiences of people receiving the study vaccine. This will help decide if the study vaccine is safe.

The total duration of taking part in the study from each group is:

Participants in Group 1 and Group 2 will take part for about 6 months, with 6 visits.
Participants in Group 3 will take part for about 8 months, with 9 visits.
Participants in Group 4 will take part for about 12 months, with 8 visits.
Participants in Group 5 will take part for about 16 to 19 months, with 11 visits.

Closest Location

To find study locations, use the location search box below.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Pneumococcal Disease

Sex

Male or Female

Age

42 days - 49 years

View more eligibility criteria on ClinicalTrials.gov

`

Join PfizerConnect

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

Who may participate

View locations for this study

Nearest Locations found

Join PfizerConnect

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

Who may participate

View locations for this study

Nearest Locations found

Are you a Healthcare Professional?